S
INCE the development of hybridoma technology 15 years ago, J2 a number of murine monoclonal antibodies against human cancer cells have been produced and many antigens have been identified. 3'~6'21 '25 The clinical use of murine monoclonal antibodies produced by mouse-mouse or mouse-human hybridomas in the treatment of human cancers has inspired new concepts for cancer diagnosis and treatmerit.6,15,19 However, there are some practical problems associated with the clinical use of foreign antibodies in humans, such as the induction of the human antimouse response, possibly reducing the efficacy of the treatment. 14 Several human monoclonal antibodies against human cancer cells have been created using lymphocytes from cancer patients. 1"5"7"8"1~ 1,~7, 22 24,27 ,28 Hagiwara and Sato ~~ reported the production of a human monoclonal antibody, CLN-IgG, made by fusing UC 729-6, 8 a 6-thioguanine-resistant human lymphoblastoid B-cell line, with lymphocytes obtained from a patient with squamous-cell carcinoma of the cervix. It has previously been reported that CLN-IgG recognized the antigen expressed in various histological types of human cancers, including malignant gliomas. 2 In this report, we describe the precise reactivities of CLN-IgG against various human glioma tissues, normal brain tissues, and cultured glioma cells. We define the antigen recognized by CLN-IgG on malignant glioma cells for the purpose of identifying the value of the antibody in the diagnosis and treatment of malignant gliomas.
Materials and Methods

Monoclonal Antibody
The derivation, properties, and purification of the human monoclonal antibody, CLN-immunoglobulin (Ig)G,* have been described in previous reportsfl ~~
Cells" and Tissues
Cells from the human glioma cell lines U-251MG, U-373MG, and KNS-42, t were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and kanamycin (50 ~g/ml), and grown in monolayer culture at 37~ in a humidified chamber with 5% CO2 and 95% air atmosphere. Tumor tissues were obtained from glioma patients undergoing surgery at Kobe University Hospital. To obtain primary cultured cells, tumor tissues were mechanically cut into fragments of about 0.5 cu ram, incubated for 30 minutes at 37~ in RPMI-1640 medium supplemented with the enzyme Disperse (1000 IU/ml),~ and passed through a 100-urn stainless steel mesh. The single cells were washed three times with RPMI-1640 medium and suspended in complete medium.
Cell Treatment
The U-251MG cells and primary cultured glioblastoma cells were treated with 1 mM Nr,O2-dibutyryl cyclic adenosine monophosphate (AMP) for 48 hours to induce cell differentiation, t8 Cells at the G~ tumor growth phase were obtained by treatment with serumfree medium for 5 days against confluent cultured cells. Cells at the G2/M phase were prepared by mitotic shaking. 2~
Irnmunoperoxidase Staining
Frozen tissue sections (6 urn) were fixed with cold acetone for 10 minutes, then washed with phosphatebuffered saline (PBS), pH 7.4, for 20 minutes. Sections were preincubated with 0.03% H202 in methanol for 20 minutes and washed with PBS for 20 minutes. Following incubation with 5% normal goat serum in PBS for 30 minutes, sections were incubated with 10 ug/ml of CLN-IgG for 60 minutes at 30~ After another wash with PBS for 30 minutes, sections were incubated with biotinylated goat anti-human IgG for 30 minutes at 30~ After a further wash with PBS for 30 minutes, sections were incubated with avidin-biotinperoxidase complex for 30 minutes at 30~ After yet another wash with PBS for 30 minutes, peroxidase reaction was initiated using 0.06% diaminobenzidine with 0.01% H202 in 50 mM Tris-HC1 buffer, pH 7.0, for 5 minutes. The sections were briefly counterstained with hematoxylin. Negative control sections were incubated with nonimmunized human IgG in place of CLN-IgG.
lmmunofluorescence Staining
Semiconfluent U-251MG cells were grown on coverslips in complete medium, washed with PBS, and fixed with cold 80% ethanol for 20 minutes at 4~ After being washed with PBS, cells were incubated with I0 ug/ml of CLN-IgG for 30 minutes at 4~ After another wash with PBS, cells were stained with fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG for 30 minutes at 4~ then incubated with 4 tzg/ ml of propidium iodine for deoxyribonucleic acid (DNA) staining. The coverslips were viewed under a fluorescence microscope.
Flow Cytometry Analysis
Cells were washed three times with PBS, and fixed with 80% ethanol for 30 minutes at 4~ Staining for CLN-IgG was performed by incubating 1 • 106 cells :~ Disperse supplied by Godo Susei Co., Tokyo, Japan.
T. Kokunai, N. Tamaki, and S. Matsumoto for 60 minutes at room temperature in CLN-IgG, 10ug/ ml. After incubation, the cells were washed three times with 0.05% Tween 20/PBS and then incubated for 30 minutes at room temperature in 20 ul of PBS containing a 1:20 dilution of FITC-labeled goat anti-human IgG. Cells incubated with nonimmune human IgG served as a control for background fluorescence.
After being washed three times with 0.05% Tween 20/PBS, the cells were preincubated with 1 mg/ml of ribonuclease for 30 minutes at 30~ then stained with propidium iodine (final concentration of 4 ug/ml). Immunofluorescence and correlated dual-parameter measurements of CLN-IgG versus DNA content were performed with a fluorescence-activated cell sorter.w The green FITC fluorescence signal was proportional to CLN-IgG levels and was measured with a 514-nm bandpass filter. The red propidium iodine fluorescence signal, corresponding to DNA content, was measured using a 560-nm filter in conjunction with a 610-nm longpass filter.
For analysis of the antigen on the cell membrane, semiconfluent cells were treated with 0.05% ethylenediaminetetra-acetic acid for 10 minutes at 37~ in order to obtain single cells, then washed with PBS containing 5% fetal bovine serum and 0.05% sodium azide. The cells were incubated for 60 minutes with 5 ug/ml of CLN-IgG at 4~ After being washed with PBS containing 5% fetal bovine serum and 0.05% sodium azide, the cells were stained with a 1:20 dilution of FITClabeled goat anti-human IgG for 30 minutes at 4~ After washing, the signal was measured with the fluorescence-activated cell sorter and stained cells were viewed under the fluorescence microscope.
For analysis of the antigen in cytoplasm, single cells were treated with 0.25% trypsin in PBS for 60 minutes at 37~ following fixation with cold 80% ethanol. Flow cytometry analysis was performed as for the analysis of the antigen on cell membrane. Treatment with 0.25% trypsin for 60 minutes at 37~ as described inhibited the expression of antigen on cell membrane (data not shown).
Imrnunoblotting
The U-251MG cells (107 cells) were solubilized with 500 ~1 of cell-lysis buffer containing 1% Triton X-100, 1% sodium deoxycholate, 0.01% sodium dodecyl sulfate (SDS), 0.15 M NaC1, 50 mM Tris-HC1 (pH 7.4), and 2 mM phenylmethylsulfonylfluoride. Cyst fluids, sera, and cerebrospinal fluid (CSF) obtained from glioma patients were lyophilized. Samples (1 mg/ml of protein concentration) were dissolved in buffer containing 2.5% SDS, 5% 2-mercaptoethanol and 0.01 M Tris-HC1 (pH 8.0), and boiled for 5 minutes at 100~ The procedure for SDS-polyacrylamide gel electrophoresis used in this study essentially followed the method of Laemmli. 13 The stacking gel contained 5% acrylamide w Fluorescence-activated cell sorter was manufactured by Becton-Dickinson, Inc., Mountain View, California. and 0.13% N,N'-methylene-bisacrylamide (Bis), and the running gel contained 10% acrylamide and 0.1% Bis. Electrophoresis was performed at room temperature for 4 hours at 20 mA to a 0.4-mm width of gel. The migration front was followed by adding 0.002% bromophenol blue to the electrode buffer. Proteins from the gels were electrophoretically transferred onto nitrocellulose filters at a constant voltage of 50 V for 3 hours as reported by Towbin, eta/. 26 The nitrocellulose filters were immersed in 3% bovine serum albumin then reacted according to the method described for immunoperoxidase staining.
Antibody-Dependent Cell Cytotoxicity
The U-251MG cells and primary cultured cells from various glioma tissues for use as target cells were mixed with sodium chromate (5~Cr) at 100 uCi/106 cells/ml and incubated for 1 hour at 37~ in a CO2 incubator. The 5 ~Cr-labeled target cells (1 x 104/well) and effector lymphocytes were incubated with or without 50 ug of CLN-IgG for 6 hours at 37 ~ in a 96-well microplate. Human peripheral lymphocytes collected from healthy donors were used as effector cells. The radioactivity of 0.1 ml of supernatant in each well was collected, and the percentage of lysis was assessed by means of the formula: cytolysis (%) = ((a -c) + (b -c)) x 100, in which a is the percentage of release (expressed as counts per minute (cpm)) in the presence of effector cells, b is the percentage of maximum release (in cpm) by 1 N HC1, and c is the percentage of spontaneous cpm with medium alone. Table 1 shows the immunohistochemical reactivity of CLN-IgG on various histological types of brain tumor and normal brain tissue. There were 51 brain tumors; seven of the eight glioblastomas (Fig. 1A) and all four anaplastic astrocytomas (Fig. 1 B) stained positively. Benign gliomas (oligodendrogliomas, ependymomas, and astrocytomas) showed a low occurrence of CLN-IgG reactivity. The heterogeneous staining by CLN-IgG was typical in tumor cells from glioblastoma specimens (Fig. 1A) . Blood vessels in tumor tissue were not stained by CLN-IgG (Fig. 1A) . Benign brain tumors (meningiomas, neurinomas, pituitary adenomas, and choroid plexus papillomas) did not stain, but tissue from two of five craniopharyngiomas did. Adult normal brain tissue (Fig. IC) and fetal brain tissue (Fig. 1D) 
Results
Immunohistochemical Characterization
FIG. 2. Immunofluorescence staining of fixed U-251MG
cells with CLN-IgG. The reactive fluorescein isothiocyanate products with CLN-IgG, especially ruffles, were found on the cell membrane. Nuclei stained with propidium iodine, x 280.
did not show any reactivity with CLN-IgG. The antigen recognized by CLN-IgG was localized in the cell membrane of U-25 IMG cells (Fig. 2) , especially ruffles. The reactivity of CLN-IgG toward U-251MG cells was resistant to treatment with sodium periodate and other modes of deglycosylation (data not shown).
Flow Cytometry
The relationship between the expression of antigen and the cell cycle was examined by flow cytometry. Flow cytometric analysis with the use of CLN-IgG showed strong positive binding to U-251 MG and KNS-T. Kokunai, N. Tamaki, and S. Matsumoto 42 cells, especially at the GriM phase compared to that at the G~ phase (Fig. 3) . When U-251MG cells were treated with cyclic AMP, they showed reduced expression of the antigen recognized by CLN-IgG, especially the expression of the antigen on cell membrane (Fig.  4) . The maximum expression of the antigen on the cell surface was detected in the cells at G2/M phase and synchronously cultured U-251 MG cells at the Go/G1 phase showed a markedly decreased expression (Fig. 4) . In primary cultured cells from glioblastomas, the expression pattern of the antigen recognized by CLN-IgG was the same as the pattern of U-251MG cells, but more marked expression during the G2/M phase was observed (Fig. 5) than at the Go/G~ phase.
I m m unoblotting
Immunoblotting analysis was used to examine the epitope of the antigen in U-251MG cells and the amount of antigen shed into cyst fluids, sera, and CSF of glioma patients (Fig. 6 ). Cell lysates of U-251MG cells under reduced conditions showed two bands with a molecular weight (MW) of 60 kD and 53 kd. These data suggest that the epitope of the antigen in U-251MG cells recognized by CLN-IgG is the same as that of a previously reported antigen. '~ The antigen recognized by CLN-IgG was detected in the cyst fluid of one glioblastoma, but was a single band with an MW of 60 primary cultured glioma cells. The ADCC activity of CLN-IgG against U-251 MG cells was l 0.81% + 1.24 % at an effector:target ratio of 40:1, and was reduced when the cells were treated with cyclic AMP (Fig. 7) . Table 2 shows the ADCC activities of CLN-IgG against primary cultured cells from various glioma tissues. The ADCC activity of CLN-IgG against the primary cultured cells of glioblastoma and anaplastic astrocytoma was 36.2% _+ 12.85% and 29.4% _+ 7.65%, respectively, but against the primary cultured cells of astrocytoma and normal brain CLN-IgG ADCC activity was very low (8.9% -+ 3.65% and 4.3% _+ 2.81%, respectively).
Antibody-Dependent Cell Cytotoxicity
Discussion
Reactivity of CLN-IgG Antibody
Human monoclonal antibody CLN-IgG reacted with malignant gliomas, especially with glioblastoma and anaplastic astrocytoma. 
Therapeutic Application
There is a potential therapeutic application for monoclonal antibodies against cancer cells because cell surface expression of the antigen is thought to be a major factor in the initial reaction of antibody-mediated immunity against cancer cells. Flow cytometric analysis and immunofluorescence staining showed that the antigen was expressed on the cell membrane of U-251MG cells and primary cultured glioblastoma cells. Moreover, flow cytometric analysis revealed that the expression of the cell-surface antigen was higher in the undifferentiated cells than the differentiated cells treated with cyclic AMP. Maximum expression of this antigen on the cell membrane was observed during the G J M phase of the cell cycle. These data suggest that the function of the antigen recognized by CLN-IgG may be related to cell proliferation.
The shedding of the antigen into body fluid is important for cancer immunotherapy. The antigen recognized by CLN-IgG was shed into the cyst fluid in only one case of glioblastoma and did not shed into the cyst fluid, serum, or CSF of any other case or into the supernatant of U-251MG cells. This shed antigen had a single molecule (MW 60 kD) in contrast to the two molecules detected in the cell lysate of U-251MG cells. This finding suggests the possibility that the shed antigen might be a degraded form of the antigen recognized by CLN-IgG. It is important for cancer immunotherapy that CLNIgG had antibody-dependent cell cytotoxicity against cells and primary cultured cells of glioblastomas and anaplastic astrocytomas. Furthermore, synergistic augmentation was reported in complement-dependent cytotoxicity against cancer cells using CLN-IgG and another human monoclonal antibody. 9 In addition, during the several years since its establishment, the clone has been stable both in CLN-IgG secretion and in specificity against cancer cells? ~
Radioimaging
Mouse monoclonal antibodies to human cancer cells have been used for immunotherapy 6'25'~ 9 and radioimaging? There are some practical problems ~ to using mouse monoclonal antibodies in clinical practice, including the induction of anti-mouse IgG after multiple administrations and the potential adverse reactions against certain normal tissues. The accumulation of anti-mouse IgG in the circulation could neutralize subsequently administered monoclonal antibodies and diminish their effectiveness. Circulating mouse monoclonal antibody-anti-idiotype complexes might lead to immunological suppression, enhancement of tumor growth, and renal dysfunction. For the above reasons, the human-human monoclonal antibody (CLN-IgG) is thought to be of possible use for immunotherapy or radioimaging of malignant gliomas, and for analysis of the humoral immune response against human malignant gliomas such as the anti-idiotype network.
